A Multi-region, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating SEP-4199 Controlled Release (CR) for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression)
Latest Information Update: 14 Oct 2024
At a glance
- Drugs SEP 4199 (Primary)
- Indications Bipolar I disorders
- Focus Registrational; Therapeutic Use
- Acronyms RELEASE 1
- Sponsors Sumitomo Pharma America; Sunovion Pharmaceuticals
Most Recent Events
- 16 Nov 2023 Status changed from active, no longer recruiting to discontinued.
- 01 Nov 2023 This trial has been discontinued in Bulgarian(Global end date: 10 Oct 2023).
- 27 Oct 2023 This trial has been discontinued in Slovakia (Global end date: 10 Oct 2023).